2025-06-10-Jefferies-邀请_中国诊断专家_关于带量采购_关税和体外诊断市场趋势的最新情况_6页_81kb

报告摘要

Summary

Event Invitation

Jefferies is inviting participation in a webinar on June 13, 2025, at 9:00 AM ET. The discussion will feature Wenxin (Vincent) Ma, General Manager of Sales and Marketing at Shandong Accurdx Biotechnology. Key topics include evolving federal reimbursement and Value-Based Pricing (VBP) policies, trade policy shifts and IVD exemptions, pricing and competitive dynamics in the local market, and emerging trends in China's In Vitro Diagnostics (IVD) market.

Equity Research Details

Report Focus: Covers Life Science Tools & Diagnostics, with equity research and recommendations.
Analysts Certified: Tycho Peterson, Matthew Stanton, Jack Melick, CPA, Priya Patel, Noah Kava, and Lauren Timmins, PhD, all certify that their views reflect personal opinions and are unrelated to compensation.
Valuation Recommendations:
- Buy: Re suggested for companies expected to provide a total return of 15% or more (e.g., DHR, QDEL, QGEN, TMO, Sysmex).
- Hold: For companies with moderate expected returns (plus 15% or minus 10%, e.g., BIO, Revvity Inc.).
- Underperform: Rated for companies likely to decline in value (minus 10% or less).
- Specific tickers and ratings include: BIO (Hold), DHR (Buy), QDEL (Buy), QGEN (Buy), RVTY (Hold), TMO (Buy), and Sysmex (Buy).
Valuation Methodology: Ratings consider market capitalization, maturity, growth/value, volatility, and expected total return; price targets incorporate DCF, EV/EBITDA, P/E, and other metrics.
Key Risks: Emphasizes potential conflicts of interest, market fluctuations, currency risks, and that past performance does not guarantee future results.

Analyst Certifications

All analysts confirm that their views in the report are personal and not influenced by compensation, ensuring objectivity where possible, subject to standard disclosures.

Disclosures Summary

Jefferies maintains a policy of independence from conflicts of interest, including potential engagements with covered companies. This report is for Jefferies clients only, and users are advised to make independent investment decisions, as information is not tailored to individual circumstances.

展开完整摘要